SSA
ABUS icon

Schonfeld Strategic Advisors’s Arbutus Biopharma ABUS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,900
Closed -$61K – 2540
2022
Q3 		$61K Buy
+31,900
New +$75.1K ﹤0.01% 2614
2022
Q1 		– Sell
-12,500
Closed -$49K – 2551
2021
Q4 		$49K Sell
12,500
-133,300
-91% -$518K ﹤0.01% 1949
2021
Q3 		$626K Buy
+145,800
New +$486K 0.01% 1166
2021
Q2 		– Sell
-12,719
Closed -$42K – 1896
2021
Q1 		$42K Buy
+12,719
New +$49.1K ﹤0.01% 1726
2017
Q4 		– Sell
-125,000
Closed -$775K – 728
2017
Q3 		$775K Buy
+125,000
New +$535K 0.07% 310

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return